We also found that inhibition of SLC1A5 enhanced the inhibitory effect of Almonertinib on NSCLC cells, which supported the idea of targeting tumor metabolic pathways to improve drug sensitivity. Here, SLC1A5 is linked to non-small cell lung carcinoma.